Skip to main content
. 2008 Jun;4(3):481–492. doi: 10.2147/vhrm.s2503

Figure 2.

Figure 2

Study 2 – Adjusted mean change from baseline to endpoint in HbA1c after 24 weeks of treatment with vildagliptin (50 mg bid) or placebo in metformin-treated patients with T2DM (p < 0.001) (Bosi et al 2007a).

Study 3 – Adjusted mean change from baseline to endpoint in HbA1c after 24 weeks of treatment with vildagliptin (50 mg bid) or pioglitazone (30 mg qd) in metformin-treated patients with T2DM; the between group difference was 0.10 ± 0.08% (95 CI: −0.05, −0.26) (Bolli et al 2008).